COMPARE · Data as of August 24, 2026
HRMY vs REGN
Verdict: Side-by-side breakdown using the Bull Rankings model. HRMY scored 88.6, REGN scored 64.0 — HRMY leads.
Compare another set
HRMY
Harmony Biosciences Holdings, Inc.
88.6
$38.68 · $2.3B
fundamentals as of
Score gap
24.6
HRMY leads
REGN
Regeneron Pharmaceuticals, Inc.
64
$835.34 · $86.0B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- CheapestHRMY12.5x
- Fastest growthHRMY+24.3%
- Strongest balance sheetREGN0.09
- Highest qualityHRMY80 / 100
- Largest discount to fair valueHRMY-75%
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
The model, pillar by pillar (0–100 each)
HRMY
stronger →← stronger
REGN
80
Qualityreturns · margins · balance sheet
66
91
Growthrevenue & earnings expansion
79
95
Valuevaluation vs sector peers
50
HRMY is stronger on 3 of 3 pillars.
Fundamentals, head-to-head
HRMY
REGN
$355mC
FCF
$3.8bB
+24.3%A-
Rev
+9.3%B
0.16B+
D/E
0.09B+
12.5xA
P/E
20.7xB+
0.44A
PEG
1.38B
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
HRMY
REGN
75% below
Price vs fair valuelower is cheaper
24% above
~-18%/yr
Growth the price implies10-yr FCF · lower = less priced in
~14%/yr
+202%
1-yr DCF upside
-29%
+298%
5-yr DCF upside
-19%
+498%
10-yr DCF upside
-3%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
HRMY
Why this score
- Durable high returns
REGN
Why this score
- Diluting shareholders
The companies
HRMYHarmony Biosciences Holdings, Inc.
Why now
Biotechnology · market cap $2.3b. 5% off the 52-week high of $40.87. Revenue growing +24%, comfortably above the S&P median. PEG 0.44 — paying under fair value for the growth rate. 10 sell-side analysts rate this a Buy with a mean 1-yr target of $46.10 (implying +19% upside).
Moat
Net margin 19% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 18% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 196% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
REGNRegeneron Pharmaceuticals, Inc.
Why now
Biotechnology · market cap $86.0b. Trading near 52-week high of $847.00 — momentum setup, limited technical margin of safety. 27 sell-side analysts rate this a Buy with a mean 1-yr target of $840.43 (implying +1% upside).
Moat
Net margin 28% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 14% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. $86.0b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk
Trading within 1% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where HRMY and REGN diverge
On the headline score the gap is 24.6 points in favor of HRMY. The widest single difference is Value, where HRMY leads by 44.6 points.
- ValueHRMY 95.0 · REGN 50.4HRMY +44.6
- QualityHRMY 80.0 · REGN 66.3HRMY +13.7
- GrowthHRMY 91.5 · REGN 78.6HRMY +12.9
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.